Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate

by Vandana Singh, Benzinga Editor

July 20, 2021 9:19 AM | 1 min read | Make a Comment

The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's ALDX ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL).
PVRL is a rare ocular lymphoid malignancy consisting of a subset of primary central system lymphoma (PCNSL) and the most common type of intraocular lymphoma.
ADX-2191 is designed to inhibit dihydrofolate reductase, an enzyme involved in cellular replication and activation.
Methotrexate is the most commonly used intravitreal medication for the treatment of PVRL.
Price Action: ALDX shares are up 7.18% at $9.85 during the premarket session on the last check Tuesday.

Posted In: Biotech News Health Care Small Cap FDA General Briefs Orphan Drug Designation

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.